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THE ROLE OF TWO HOMOLOGOUS E3 LIGASES IN MUSCLE PHYSIOLOGY 
 
Gabrielle Gloston, B.S. 
 
Advisory Professor: Zheng Chen, Ph.D.  
Ubiquitin-mediated proteasomal degradation is an essential cellular function 
that is coordinated by three key components: E1 ubiquitin activating enzyme, E2 
ubiquitin conjugating enzyme, and E3 ubiquitin ligases. There are an estimated 600 
E3 ligases, some of which share high sequence homology; however, the functional 
significance often remains unknown. FBXL3 and FBXL21 are two homologous E3 
ligases that have previously been reported to dictate circadian periodicity, with 
FBXL3 being the dominant E3 ligase and FBXL21 playing a regulatory role. A recent 
Yeast Two-Hybrid screen revealed a new shared target of FBXL3 and FBXL21: 
Telethonin (also known as TCAP). TCAP is a sarcomeric z-disc protein expressed in 
cardiac and skeletal muscle that is critical to proper structure and function of 
muscles. Through preliminary experiments, we identified TCAP as a novel shared 
target substrate of FBXL3 and FBXL21. Here we report that FBXL3 and FBXL21 
both accelerate TCAP degradation; however, FBXL21 is the more potent E3 ligase. 
This novel finding underlines the importance of substrate specificity and serves as a 
paradigm for future mechanistic studies of E3 ligase homologous pairs. Additionally, 
the findings reported here will facilitate further studies investigating the role of 
FBXL3/21 in muscle physiology. 
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CHAPTER 1: INTRODUCTION 
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1. Introduction  
There are over 600 E3 ligases in the human genome, many of which share 
high sequence homology with a small subset of other E3 ligases; however, their 
functional relationship often remains unknown. Additionally, each of these ligases 
are capable of having multiple target substrates, creating a variety of E3 ligase-
substrate combinations (Harper et al 2012). FBXL3 and FBXL21 are two 
homologous E3 ligases that were previously reported to control circadian periodicity 
through antagonistic activity on their shared target substrates, CRYPTOCHROME 
(CRY) 1 and 2. In relation to CRYs, FBXL3 is the predominant E3 ligase that 
promotes degradation in the nucleus and FBXL21 plays a regulatory role by 
protecting CRYs in the cytoplasm (Yoo et al 2013).  
It is well known that circadian clocks exist within a majority of cells throughout 
the body, including the muscular system (Harfmann et al 2015). In fact, skeletal 
muscles heavily rely on the positive regulators of the circadian oscillator, Bmal1 and 
Clock, which have been shown to affect both structure and function of skeletal 
muscle when genetically disrupted in mice (Andrews et al 2010). Furthermore, 
multiple independent studies now suggest that muscle physiology is tightly clock-
regulated, making skeletal muscle a suitable candidate to screen for novel protein 
targets of FBXL3 and FBXL21 (Harfmann et al 2015; Podobed et al 2014; Mayeuf-
Louchart et al 2015).  
In a Yeast Two-Hybrid screen, we identified TCAP (also known as Telethonin) 
as a shared target substrate of FBXL3 and FBXL21. TCAP is a cytoplasmic protein 
that is integral to sarcomeric Z -disc and -line structure and function in both cardiac 
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and skeletal muscle cells, respectively (Valle et al 1997). Interestingly, TCAP has 
been shown to be circadian regulated at the mRNA level in cardiac muscle and 
mutations in TCAP have been associated with Limb Girdle Muscle Dystrophy 
(Podobed et al 2014; Moreira et al 2000). Our lab found that FBXL3 and FBXL21 
tightly and specifically bind to TCAP, with E3 ligase activity on TCAP that opposed 
the previous paradigm discovered with the CRY proteins. When ectopically 
expressed, FBXL21 potently accelerated TCAP degradation, whereas FBXL3 
showed a much more diminished effect. Therefore, FBXL3 and FBXL21 play distinct 
roles in the degradation of CRYs and TCAP. Given the crucial role that TCAP plays 
in the structure and function of skeletal muscle, we suspect that these homologous 
E3 ligases serve as important regulators of muscle physiology, just as they govern 
periodicity in the circadian clock. 
1.1 Ubiquitin-mediated protein degradation 
 Ubiquitin-mediated protein degradation is a serial, enzymatic reaction that 
targets proteins for degradation and is essential to proper cellular functioning 
(Harper et al 2012). In fact, disruption of the ubiquitin-proteasome system has been 
associated with serious physiological consequences, such as cancers and 
neurodegeneration (Welcker and Clurman 2008; Frescas and Pagano 2008; Jin and 
Youle 2012). The study of ubiquitin signaling has only been recently advanced within 
the last decade. It is currently known that eukaryotes have 2 E1 enzymes, 40 E2 
enzymes, and about 600 E3 enzymes. In order to facilitate the proper execution of 
protein turnover (and several other ubiquitin-regulated cellular functions), ubiquitin 
networks are organized in a finely tuned spatiotemporal fashion (Grabbe et 2011). 
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 The three major components that are responsible for orchestrating the 
ubiquitylation process are: E1 (ubiquitin activating enzyme), E2 (ubiquitin 
conjugating enzyme), and E3 (ubiquitin ligase) (Harper et al 2012). Ubiquitin (Ub) is 
first activated by the E1 enzyme (Ub activating enzyme) in an ATP-dependent 
manner and then becomes Ub-adenylate (ADP). Once activated, Ub is able to form 
a thioester bond with one of the 40 E2 enzymes (conjugating enzymes). E2 
conjugating enzymes play an important role in determining the number of Ub 
molecules attached to a protein as well as the chain linkage type associated with 
proteins that are poly-ubiquitinated (Ye and Rape 2009). There are three major 
groups of E3 ligases (HECT, RING, or RBR), but regardless of the type, Ub is 
transferred from the E2 conjugating enzyme to the substrate. Ultimately, proteins are 
either monoubiquitylated, multi-monoubiquitylated or poly-ubiquitylated; these 
ubiquitylation modifications are a result of the combination of specific E2 and E3 
enzymes.  
 Despite the importance of ubiquitin-mediated protein degradation, a large 
number of E3 ligases remain poorly characterized. Substrates have been difficult to 
identify partly because of the transient nature of degradative ubiquitylation targets, in 
addition to the weak interactions that typically occur between an E3 ligase and its 
substrate (Harper et al 2012). Before advancements in proteomic technology, 
substrates were identified by screening for conserved targeting sequences in 
proteins throughout the human genome that matched the targeting sequences in 
already identified E3 ligase substrates (Koepp et al 1999; Zachariae and Nasmyth 
1999; Harper et al 2002; Willems et al 1999). According to the most recent 
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predictions (based on E3 functional domains), there are over 600 E3 ligases in the 
human genome, a number of which remain completely unstudied (Deshaies and 
Joazeiro 2009). 
1.2 The mammalian circadian molecular oscillator  
 The circadian system has evolved to help the body anticipate predictable 
environmental changes, allowing the body to optimize its biological processes 
throughout Earth’s 24-hour cycles of light and dark. Circadian rhythms are generated 
by the activity of core clock circadian genes in what is known as the mammalian 
circadian molecular oscillator. This oscillator is ubiquitously expressed in individual 
cells throughout most organs in the body and functions autonomously. The most 
important circadian clock is located in the suprachiasmatic nucleus (SCN), which 
contains around 20,000 neurons with individual molecular oscillators that “tick” in 
synchrony throughout the entire SCN. A simplified schematic of the mammalian 
circadian molecular oscillator is pictured below in Figure 1. The core molecular 
oscillator consists of both positive and negative components. CLOCK and BMAL1 
are basic helix-loop-helix/PAS (bHLH/PAS) transcription factors that heterodimerize 
and translocate to the nucleus, where they bind to the E- (CACGTG or CACGTT) 
box cis-regulatory elements of several circadian genes, including the two other core 
circadian genes, Per and Cry. Once bound, these genes are transcriptionally 
activated, produce proteins that heterodimerize and then translocate from the 
cytoplasm to the nucleus. Once in the nucleus, this PER/CRY complex 
transcriptionally represses CLOCK/BMAL1, indirectly repressing their own 
transcription. This negative transcriptional regulation serves as the end of a full 
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circadian period and through additional posttranscriptional and posttranslational 
steps, transcriptional repression is relieved via proteasomal degradation of 
PER/CRY (Lowery and Takahashi 2011). 
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Figure 1: The mammalian circadian molecular oscillator. The molecular oscillator is 
ubiquitously expressed throughout most cells in the body and the fluctuating activity of its 
protein products results in circadian rhythms. The core feedback loop consists of BMAL, 
CLOCK, PER and CRY. BMAL & CLOCK heterodimerize & transcriptionally activate 
clock genes like Per and Cry, serving as the positive arm of this feedback loop. Near the 
end of a circadian period, PER & CRY bind to BMAL & CLOCK, serving as a 
transcriptional repressor of both the positive and negative arm of this core loop.  
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1.3 The role of FBXL3 & FBXL21 in the circadian clock  
 The mammalian SCF ubiquitin ligase is a multi-protein complex that is crucial 
to post-translational regulation of cellular timing via proteasomal degradation. It is 
characteristically composed of Skp1, Cul1, and an F-box protein (Cardoza and 
Pagano 2004). The F-box protein family is the substrate recognition component of 
the SCF ligase and is typically named according to their substrate-binding domain 
(Cenciarelli et al 1999; Winston et al 1999).  Currently, the F-box family includes 
FBWs, FBLs, and FBXs. The FBW family includes F-box proteins featuring 
substrate-binding domain with WD-40 repeats. FBL proteins have substrate-binding 
domains with leucine-rich repeats (LRRs). The last category of F-box proteins are 
the FBXs, which have neither WD-40 repeats nor LRRs in their substrate-binding 
domains (Cardoza and Pagano 2004). The full spectrum of protein substrates are 
still unknown for many F-box proteins; therefore, the cellular function of many E3 
ligases remains unknown. It is expected that these proteins target diverse substrates 
and have many different cellular functions, given the variety of structural 
compositions currently known (Kipreos and Pagano 2000). 
 An FBXL3 mutant mouse line (Overtime, Ovtm) was derived from a large-
scale forward ENU mutagenesis screen and was found to have a circadian period of 
25.8 hours. Through positional cloning and genetic complementation, a point 
mutation in Fbxl3 was revealed to convert isoleucine to threonine at residue 364. 
This mutation is mapped to a region between two leucine rich repeat (LRR) domains 
(LRR 10 and LRR 11) located in the C terminus of Fbxl3. Ovtm mice showed a 
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change in circadian gene and protein expression. PER protein levels were 
significantly reduced in liver tissue, while CRY2 protein levels showed significant 
elevation. All other core clock machinery, such as CLOCK, BMAL1, and CRY1 
showed no significant response to the semidominant, autosomal Ovtm mutation. 
This mouse model served as genetic evidence that FBXL3 may act as an E3 
ubiquitin ligase that targets CRY proteins (Cardoza and Pagano 2004). Cellular 
studies showed that while FBXL3 typically promote proteasomal degradation of 
CRY, FBXL3OVTM stabilized CRY, resulting in an overall elevation of CRY protein 
levels. Siepka et al (2007) concluded that the lengthened circadian period and 
complementary phenotypic alterations induced by the Ovtm mutation was caused by 
an inefficient FBXL3 protein and transcriptional repression via CLOCK and BMAL1 
(Siepka et al 2007).  
Recently, another ENU mutagenesis-derived mouse lined called Past-time 
was found to have a short circadian period (22.91 hours). Researchers mapped the 
mutation to the Fbxl21 gene, more specifically to a point mutation at nucleotide 787 
in the 5th exon. Moreover, this mutation causes a conversion of glycine to glutamic 
acid at residue 149 in the amino acid sequence, which is expected to destabilize the 
LRR domain of FBXL21 protein (Yoo et al 2013). Although small, this mutation is 
significant for the functionality of FBXL21 as an E3 ligase because LRR domains 
typically facilitate protein-protein interactions via substrate recognition (Kobe and 
Kajava 2001). In vivo work revealed that the Psttm mutation affected clock gene 
expression by elevating Per1/2 and Cry1/2 mRNA levels in the cerebellum and 
moderately so in mouse liver. Clock-controlled genes like Rev-erbα, Dec2, and Dbp 
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were also elevated in liver tissue. Interestingly, CRY protein levels were not elevated 
as expected and CRY2 levels were actually reduced, suggesting that the Psttm 
mutation affected protein stability leading to a destabilization of CRY2 protein levels 
(Yoo et al 2013).  
 FBXL3 and FBXL21 are two homologous E3 ubiquitin ligases that work in 
direct opposition to tightly regulate circadian periodicity in mammals. The circadian 
clock is driven by a molecular oscillator that consists of two interlocked loops (Ko 
and Takahashi 2006). The core loop is composed of a positive (CLOCK and BMAL1) 
and negative (PER1/2 and CRY1/2) arm. Over the course of a single circadian 
period, Per and Cry products are translocated to the cytoplasm where they 
heterodimerize, return to the nucleus, and eventually repress CLOCK/BMAL1 
transcriptional activation, thus turning off their own transcription.  When mutated, 
FBXL3 and FBXL21 can either lengthen or shorten the circadian period by 
modulating CRY protein levels. Further molecular studies based on the initial in vivo 
findings revealed that FBXL3 is the active E3 ligase for CRY in the nucleus and 
FBXL21 has dual roles (pictured in Figure 2). In the nucleus, FBXL21 is a regulatory 
E3 ligase that antagonizes FBXL3 and protects CRY. In the cytoplasm, FBXL21 is a 
weak active E3 ligase for CRY (Yoo et al 2013). This was the first study to elucidate 
such a unique homologous E3 ligase paradigm. Discovering one substrate of an F-
box protein does not reveal the full gamut of its cellular functions; instead, an E3 
ligase typically has multiple target substrates. It is important to note that FBXL21 is 
subject to circadian regulation and is a paralogue of FBXL3, with ~85% conserved 
amino acid residues between the two (Yoo et al 2013). It is therefore plausible that 
10 
 
FBXL3 and FBXL21 could share a circadian-regulated target substrate in a similar 
paradigm as the one mentioned here with CRY.  
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Figure 2: The role of FBXL3 & FBXL21 in the circadian clock. FBXL3 acts as the 
active E3 ligase, promoting CRY ubiquitin-mediated protein degradation. FBXL21 is 
present in both the nucleus & cytoplasm & therefore plays two roles with respect to 
its target substrate CRYs. FBXL21 in the nucleus antagonizes FBXL3, thereby 
protecting CRYs from degradation; however in the cytoplasm, FBXL21 promotes 
CRY ubiquitin-mediated protein degradation.   
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1.4 Circadian influence on muscle physiology 
 The human body is composed of almost 50% skeletal muscle (Goodpaster et 
al 2000; Hoppeler and Fluck 2002). Aside from enabling movement, skeletal muscle 
plays important roles in maintaining overall health. Skeletal muscle serves as an 
amino acid reservoir, a major site for postprandial glucose storage, and also an 
endocrine tissue (Ripperger et al 1995; Defronzo et al 1981; Ferrannini et al 1988; 
Febbraio and Pederson 2002). Recently, research groups have discovered circadian 
gene expression via expression profiling in skeletal muscle tissue, suggesting that 
up to 2,300 genes are circadian-regulated (McCarthy et al 2007; Pizarro et al 2013). 
The role of the circadian system is still not completely known; however, it is plausible 
that the circadian system plays multiple roles in the overall structure and function of 
skeletal muscle, given the number of muscle-specific clock-controlled genes 
(Harfmann et al 2015). Table 1 shows more examples of muscle-specific clock-
controlled genes that have physiological implications in several aspects of the proper 
functioning of skeletal muscle. These genes are typically transcriptionally regulated 
by core clock genes Clock and Bmal1.  
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Table 1 Skeletal muscle-specific clock-controlled genes 
Clock-controlled gene Physiological 
Implication 
Reference 
MyoD1 Glucose metabolism Andrews et al 2010 
Myogenin Morphology, 
myogenesis 
Shavlakadze et al 2013 
Telethonin, Titin-cap 
(TCAP) 
Muscular dystrophy Podobed et al 2014 
Ucp3 Fatty acid oxidation in 
skeletal muscle cells 
MacLellan et al 2005 
 
 
1.5 Telethonin, a novel target substrate of both FBXL3 and FBXL21  
Skeletal and cardiac muscle both require actin and myosin proteins for proper 
contractile movements. However, it is only in the cardiac and skeletal muscle that 
organized patterns of actin and myosin are bundled together into sarcomeres, which 
form the basic contractile unit in striated muscle. The sliding motion of thick (myosin) 
and thin (actin, tropomyosin, and troponin) filaments within sarcomeres allows 
muscle contraction to occur, with each sarcomere being divided by z-discs (in 
skeletal muscle, z-line in cardiac muscle). This is also where thin (actin, 
tropomyosin, and troponin) filaments are anchored. These z-discs are highly protein-
enriched areas of striated muscle, which is thought to be composed of z-disc protein 
complexes (Faulkner et al 2001). Although some advances have been made, the 
overall molecular organization of these z-disc proteins is still uncertain. 
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Figure 3: Schematic of Telethonin (TCAP). TCAP is a sarcomeric Z-disc protein that is 19kDa 
and sits at the end of TITIN protein. It is a critical regulator of both z-disc structure & function.  
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Our lab recently identified Telethonin, also known as Titin cap or “Tcap”, as a 
shared target substrate of FBXL3 and FBXL21. Tcap is a small (19kDa), cytoplasmic 
protein that is expressed exclusively in the heart and skeletal muscle & is one of the 
most abundant transcripts in striated muscle (Valle et al 1997). TCAP protein is 
developmentally-regulated, as it has been shown to be expressed at lower levels in 
neonatal animals than in adult animals. This gradual increase in expression was also 
observed in C2C12 cells during myofibrillogenesis, which validated the in vivo data 
(Mason et al 1999). Tcap (shown in Figure 3) co-localizes with actin in the thin 
filaments of the Z-disc (Gregorio et al 1998). Within the sarcomere, Tcap binds to 
two other z-disc proteins—FATZ and titin. In order to properly bind to titin, the first 
140 amino acid residues of the protein must bind with the Z1 and Z2 Ig-like N-
terminal repeat region of titin (Mues et al 1998). Interestingly, Tcap and its protein 
product show clear circadian, diurnal expression patterns in mice and blunted cyclic 
expression in circadian mutant mice (Podobed et al 2014). 
 Although small, Tcap is essential to proper structure and function of cardiac 
and skeletal muscle. At least two different mutations in Tcap have been associated 
with a form of autosomal recessive limb-girdle muscular dystrophy (AR LGMD) type 
2G. This form of the disease has a milder phenotype than other genetically distinct 
types of AR LGMD. Clinical features include significantly weakened distal leg 
muscles, calf hypertrophy, and elevated serum creatine-kinase levels. Many of these 
patients eventually lose the ability to walk near middle age. Moreira et al 200 
showed that these particular mutations affect the carboxy-terminal region of the 
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Tcap gene, which then has the potential to affect the sarcomeric structure of skeletal 
muscle (Moreira et al 2000). LGMD2G has been modeled in a TCAP knockout 
mouse that has a null mutation in the TCAP gene. Interestingly, this mouse exhibits 
a much less severe phenotype compared to LGMD2G patients, with the biggest 
impact in balance and muscle stiffness (Markert et al 2010). The disparity between 
the human and mouse phenotypes is most likely due to the mutation type—null (KO 
mouse) vs dominant negative (patients). Moreover, mutations in the Titin gene itself 
have been associated with dilated cardiomyopathy (DCM), which causes systolic 
dysfunction and ventricular dilation. (Itoh-Satoh et al 2002). TITIN is a large protein 
that is also expressed in cardiac and skeletal muscle and has been shown to interact 
with sarcomeric proteins, including TCAP (Bang et al 2001). Here, researchers 
found that two of the mutations (Val54Met and Ala743Val) mapped to the Z-line 
portion of Titin decreased TITIN protein’s ability to bind to its usual sarcomeric 
targets, one of them being TCAP; therefore, a subset of Titin mutations affect 
sarcomeric assembly via TCAP (Itoh-Satoh et al 2002). Considering Tcap’s vital role 
in cardiac and skeletal muscle physiology, it is plausible that FBXL3 and FBXL21 
regulate skeletal muscle physiology by tightly controlling TCAP protein levels.    
  
1.6 Central hypothesis & specific aims 
We hypothesize that FBXL3 and FBXL21 coordinately regulate skeletal muscle 
physiology via ubiquitin-mediated protein degradation of their shared target 
substrate TCAP.  
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Specific Aim 1: To characterize the circadian timing of TCAP expression in wild-type 
and Past-time muscle tissues. We will collect skeletal (gastrocnemius) and cardiac 
muscle tissue from adult wild type and FBXL21 mutant (Psttm) mice at CT 0, 4, 8, 
12, 16, and 20 to investigate endogenous protein expression of TCAP over a full 
circadian cycle. We hypothesize that TCAP expression in Psttm muscle tissue will 
display an abnormal (overall increase) expression due to the point mutation in 
Fbxl21.   
 
Specific Aim 2: To assess the roles of FBXL3 and FBXL21 in TCAP degradation. We 
will measure TCAP protein stability in the presence of either E3 ligases to determine 
how FBXL3 and FBXL21 affect TCAP degradation. We hypothesize that FBXL21 will 
decrease TCAP stability and FBXL3 will increase TCAP stability. 
 
Specific Aim 3: To construct a viral expression vector for the overexpression of 
FBXL3 and FBXL21 in a skeletal muscle in vitro model. We will remove FBXL3/21 
insert from the pCMV10-3XFlag and subclone into the pFUW lentiviral vector to 
overexpress FBXL3/21 in vitro. We hypothesize that FBXL3/21 will be sufficiently 
expressed in vitro. 
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CHAPTER 2: MATERIALS & METHODS 
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2.1 Mouse strains 
C57BL/6J (Stock # 000664) mice were purchased from Jackson Laboratory (Bar 
Harbor, ME). Psttm/Psttm (“Past-time”) mutant mice were cloned by Dr. Seung-Hee 
Yoo. The Past-time mouse line was generated from ENU mutagenesis as previously 
described (Yoo et al 2013). All mice were group-housed according to genotype and 
maintained under LD 12:12 conditions with food and water provided ad libitum. All 
animal care and procedures were approved by the Animal Care and Use Committee 
of the University of Texas Health Science Center in Houston.   
2.2 DNA extractions & Past-time genotyping 
Genotyping was performed using DNA derived from a 2 mm tail tip extracted 
from each Past-time mouse. To extract genomic DNA, tail tips were placed in a 1.5 
mL micro-centrifuge tube and heated to 95⁰C with 90 uL 50 mM NaOH for 45 
minutes. To neutralize the extract, 10 uL 1M Tris (pH 4.7) was added to each 
sample and the DNA extract was vortexed. To genotype by PCR analysis, the DNA 
extract was diluted 1:5 with nuclease-free water and stored at 4⁰C.  
Past-time mice were maintained as homozygote breeding pairs (2 PSTM 
homozygote females, 1 PSTM homozygote male), so the resulting progeny did not 
require genotyping. Past-time genomic DNA was amplified during PCR using 
forward (5’CAGAACTCGGTTGCTGGATT-3’) and reverse 
(5’CAGCAACTCCGTCTTTCCTC-3’) primers at 100uM.  PCR products are purified 
using the QIAquick Gel Extract kit (Qiagen) and then submitted to GeneWiz for 
sequencing to detect single nucleotide polymorphisms. The PSTM wild-type and 
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PSTM homozygous sequences are as follows: CCTTGGGATTG and 
CCTTGGAATTG. 
2.3 Tissue collection 
C57BL/6J and Psttm mice were maintained in LD 12:12 and then moved to constant 
darkness (DD) 36 hours prior to tissue collection at 13 weeks of age. Mice were 
sacrificed by cervical dislocation under infrared lights at CT 0, 4, 8, 12, 16, and 20. 
Gastrocnemius and tibialis anterior tissue was harvested under normal white light. 
Tissue was sectioned into 50-100mg pieces, immediately snap-frozen in dry ice and 
then placed in a pre-chilled 1.5mL micro-centrifuge tube to prevent proteasomal 
degradation. Prior to protein extraction, tissue samples were stored at -80⁰ Celsius. 
A one-inch portion of the tail was also collected and frozen to verify the genotype of 
any given mouse, if necessary, for future experiments. 
2.4 Protein extractions 
Frozen mouse tissue was immersed in a total of 500uL of cold extraction 
buffer & then homogenized with an electric homogenizer. To fully disrupt the lysate, 
samples were vortexed at 3000rpm for 30 seconds every 5 minutes for a total of 15 
minutes. Samples were then centrifuged at 13,000 rpm for 20 minutes at 4⁰ C and 
the supernatant was aspirated (avoiding any lipid or other insoluble materials) into a 
fresh tube and kept on ice for protein quantification. To quantify protein 
concentrations, we performed the Bradford Assay as previously described Bradford, 
MM 1976 and measured the optical density (OD) of each sample at 595 nm on the 
Tecan plate reader. Lysate was diluted with EB first until all samples were 2ug/uL 
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and then with one-fifth volume 5x Laemmli loading buffer and lastly boiled at 95⁰ C 
for 5 minutes to denature the quarternary structure of the protein samples. 
2.5 Immunoblotting 
10-12ug of WT and Psttm muscle lysate was resolved by SDS-PAGE and Western 
Blotting analysis. The following antibodies were used: TCAP 1:1000 (BD 
Biosciences, Abcam), FBXL21 1:2000 (generated as specified in Yoo et al 2013), 
FBXL3 1:3000 (generated as specified in Yoo et al 2013), GAPDH 1:10000 
(Ambion), FLAG 1:1000 (Sigma).  Relative protein abundance was quantified using 
ImageJ (Schneider et al 2012) and two-way ANOVAs were performed to measure 
differences between WT and Psttm expression across circadian time on GraphPad 
Prism software. Error bars represent ± SEM (n=3). 
2.6 Cell Culture & Transfection 
The C2C12 cell line (ATCC) is commonly used to model skeletal muscle 
differentiation. C2C12 myoblasts were thawed from a frozen stock and maintained as 
myoblasts in high glucose + glutamine Dulbecco’s Modified Eagle Medium (DMEM) 
with 10% Fetal Bovine Serum (FBS) and 1% Penicillin/Streptomycin. To prevent 
differentiation into myotubes, C2C12 cells were subcultured at 80-90% confluency.  
To perform the TCAP protein degradation assay, C2C12 cells were plated into 
two 6-well plates at 1 ˣ 105 per well 17 hours before transfection. Cells were then 
transfected with Tcap with or without Fbxl3 or Fbxl21 constructs using Effectene 
transfection reagent (Qiagen). 40ug/mL cycloheximide (CHX) was then added to 
each well 24 hours after transfection. To confirm functionality of the FBXL3/21-
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expressing lentivirus constructs, HEK 293T cells were plated at 1 ˣ 105 per well in a 
6-well plate, then transfected 17 hours later using Effectene transfection reagent 
(Qiagen). 24 hours after transfection, FBXL3/21 expression was confirmed via 
confocal microscopy and immunoblotting. To produce the FBXL3/21 lentiviruses, 
293T cells were plated in a polyD lysine-coated 10cm dish at 6.0 ˣ 106 in antibiotic-
free 10% FBS media. The 293T cells were transfected with pCMV-deltaR8.91 and 
pVSV-G packaging vectors with Lipofectamine 2000 transfection reagent (Thermo 
Fischer Scientific). 12-16 hours after transfection, the Lipofectamine-containing 
media was replaced with complete media for 293T cells. 48 hours later, the virus-
containing supernatant was transferred to a polypropylene tube and centrifuged at 
4,000 rpm for 10 minutes to remove the remaining 293T cells. The virus was then 
filtered using a 0.45 um cellulose acetate filter and stored at 4⁰ C for short-term 
storage and -80⁰ C for long-term storage.   
2.7 Plasmids 
Fbxl3 and Fbxl21 cDNA was synthesized as specified in Yoo et al (2013). 
2.8 TCAP degradation assay 
C2C12 cells were treated with 40ug/mL of cycloheximide for 0, 2, 4, or 6 hours. 
Cycloheximide is a commonly used reagent to inhibit protein synthesis by preventing 
the elongation step of eukaryotic translation [Schneider-Poetsch et al 2010]. At the 
end of each indicated treatment time, C2C12 cells were lysed and used for 
immunoblotting. Half-life parameter K was calculated using one-phase decay. 
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Statistical difference between half-life parameter K was calculated by one-way 
ANOVA. Error bars represent ± SEM (n=3). 
2.9 Lentiviral construction 
To improve transfection efficiency of C2C12 cells, a lentivirus system with GFP 
markers has been employed for the muscle differentiation experiment. Full-length 
Fbxl3 and Fbxl21 cDNA (tagged with a Flag sequence) was digested from its original 
vector, pCMV10-3XFlag (Sigma) and subcloned into the pFUW lentivirus vector. To 
confirm the insert sequence, lentivirus vectors expressing Fbxl3 and Fbxl21 were 
submitted to GeneWiz. To confirm functionality of these lentivirus vectors in vitro, 
293T cells were transfected with both vectors using Effectene reagent (Qiagen), 
lysed 24 hours later, and Fbxl3 and Fbxl21 expression was confirmed via 
immunoblotting.   
2.10 Statistical Analysis 
All statistical analysis was performed in GraphPad Prism (Version 5). Two-
way ANOVA analysis was performed to compute the differences in protein 
expression between WT and Psttm muscle tissues across six circadian time points. 
Two-way ANOVA analysis helps to determine how the dependent variable is 
affected by two variables or factors. In this case, both the genotype of each mouse 
that the muscle tissue was collected from and circadian time contribute to the 
response (protein expression). Error bars represent ± SEM (n=3). 
Half-life of TCAP protein alone or in the presence of FBXL3/21 was 
determined using one-phase decay analysis, where K is the half-life parameter. This 
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statistical test was chosen because cycloheximide treatment results in only one 
decay phase as opposed to multiple phase decays. One-way ANOVA analysis was 
performed to compute the statistical difference between half-life parameter, K, for 
each condition. Error bars represent ± SEM (n=3). 
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CHAPTER 3: RESULTS 
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3.1 Circadian timing of TCAP protein expression in skeletal muscle 
 Preliminary experiments validated our novel finding that TCAP is a shared 
protein target of E3 ligases FBXL3 and FBXL21. This homologous pair was shown 
to differentially affect TCAP expression in HEK293T cells. Yoo et al (2013) reported 
that FBXL3 was the dominant E3 ligase in CRY protein degradation, while FBXL21 
was considered to be a regulatory E3 ligase.  Unexpectedly, FBXL21 was much 
more potent in TCAP degradation than FBXL3, suggesting that FBXL21 is the 
primary E3 ligase in ubiquitin-mediated protein TCAP degradation. These newly 
identified FBXL3/21-TCAP interactions directly oppose the previous mechanism 
established in (Yoo et al 2013) in which FBXL3 was the active E3 ligase and 
FBXL21 was predominantly a regulatory ligase for the CRYPTOCHROME (CRY) 
substrates. This difference in E3 ligase-substrate activity highlights the importance of 
substrate specificity in characterizing E3 ligases’ cellular function(s). TCAP is ranked 
as the 12th most abundant transcript in skeletal muscle tissue (Valle et al 1997) and 
is a circadian-regulated transcriptional target (Podobed et al 2014). We therefore 
isolated WT and Psttm gastrocnemius (skeletal) muscle to characterize the circadian 
timing of TCAP protein expression. We hypothesize that the instability of Fbxl21 in 
the Psttm mutant mice will lead to elevated TCAP protein levels throughout the 
circadian cycle under normal (12:12 LD conditions). 
We observed a circadian oscillation of TCAP protein with a peak at CT16 in 
WT mice (Figure 4), whereas the Psttm mutation caused a significant increase in 
overall TCAP protein expression. This increase in expression is consistent with our 
sub-hypothesis that TCAP protein expression would be elevated throughout the 
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circadian cycle due to the lack of stability in Fbxl21 in Psttm mice. We also observed 
a circadian oscillation in FBXL21 protein, with a slight phase advance in expression 
compared to TCAP protein expression. FBXL21 protein expression is unstable 
throughout the circadian cycle in Psttm skeletal muscle, as expected (Yoo et al 
2013). FBXL3 was constitutively expressed in both WT and Psttm tissue, consistent 
with the literature that shows that FBXL3 is not circadian regulated (Yoo et al 2013). 
Most importantly, two-way ANOVA analysis shows significant (p<0.001) genotype 
effect on TCAP and FBXL21 protein expression, and TCAP protein expression is 
elevated throughout the entire circadian cycle in PSTM homozygous mice compared 
to PSTM WT mice. Interestingly, when TCAP protein expression is highest (CT16), 
FBXL21 protein expression was low as shown in Figure 5A. This observation is 
consistent with our preliminary results, which implies that TCAP expression should 
be highest when the active E3 ligase (FBXL21) is not present or expressed at 
relatively low levels.  
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Figure 4: Circadian timing of TCAP protein expression in skeletal muscle. Mice 
were sacrificed at CT 0, 4, 8, 12, 16, and 20 under infrared lights and Western Blots 
were performed with whole protein lysate (extracted from gastrocnemius muscle) 
using the indicated antibodies. Representative Western Blots are shown to the left 
with corresponding quantifications on the right. In the plots, blue data points denote 
WT mice and red data points represent PSTM homozygote protein expression. Two-
way ANOVA analysis shows significant (p<0.001) differences between WT and 
Psttm protein levels of TCAP and FBXL21. Error bars represent mean ± SEM (n=3).  
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3.2 Circadian timing of TCAP protein expression in cardiac muscle 
 TCAP is also a critical regulator of sarcomeric z-disc structure and function in 
cardiac muscle (heart) (Valle et al 1997).  To further characterize TCAP protein 
expression throughout the circadian cycle, we isolated WT and Psttm heart tissue. 
Again, we observed a circadian oscillation of TCAP protein in WT heart tissue with a 
peak at CT16 (Figure 6) and significantly elevated levels of TCAP protein throughout 
the circadian cycle. FBXL21 protein expression displayed a moderate oscillatory 
pattern across the circadian cycle in WT mice, but was unstable in Psttm mice, due 
to the point mutation in Fbxl21. FBXL3 protein showed slight fluctuations in 
expression throughout the circadian cycle in WT cardiac muscle, but this is not due 
to circadian regulation. FBXL3 protein expression in Psttm cardiac muscle was 
found to be unstable. Overall, two-way ANOVA analysis showed significant 
(p<0.001) genotype effect on TCAP protein expression, and again TCAP protein 
expression is elevated throughout the entire circadian cycle in cardiac muscle of 
PSTM homozygous mice compared to PSTM WT mice. 
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Figure 5: Circadian timing of TCAP protein expression in cardiac muscle. Mice were 
sacrificed at CT 0, 4, 8, 12, 16, and 20 under infrared lights and Western Blots were 
performed with whole protein lysate (extracted from heart tissue) using the indicated 
antibodies. Representative Western Blots are shown to the left with corresponding 
quantifications on the right. In the plots, blue data points denote WT mice and red data points 
represent PSTM homozygote protein expression. Two-way ANOVA analysis shows significant 
(p<0.001) differences between WT and Psttm protein levels of TCAP. Error bars represent 
mean ± SEM (n=3). 
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3.3 TCAP degradation by FBXL3 or FBXL21  
 Based on our Yeast Two Hybrid screening results, we performed a protein 
half-life experiment to determine the stability of TCAP protein with or without FBXL3 
or FBXL21 in HEK293T cells. Unlike the previous study of these two homologous E3 
ligases, TCAP was least stable in the presence of FBXL21, suggesting that FBXL21 
is the active E3 ligase in TCAP ubiquitin-mediated protein degradation. Although 
unexpected, this change in E3 ligase activity is reasonable, considering that FBXL21 
and TCAP are both either predominantly or completely cytoplasmic proteins, in 
addition to both being subject to circadian regulation (Yoo et al 2013; Valle et al 
1997). Because this experiment was performed in a cell line that lacks physiological 
relevance to cardiac or skeletal muscle, the half-life experiment was then performed 
in C2C12 myoblasts. The C2C12 cell line is derived from primary mouse myoblasts 
and can be differentiated into myotubes, thus making this cell line effective for 
modeling mammalian myogenesis (Burattini et al 2004).  
 To measure the half-life of TCAP protein, C2C12 cells were co-transfected 
with TCAP and either FBXL3 or FBXL21. 24 hours after transfection, cells were 
treated with cycloheximide (CHX), a protein synthesis inhibitor, which effectively 
facilitates measurement of protein degradation of pre-existing proteins. Interestingly, 
our TCAP degradation assay results differed from our preliminary results (in 
HEK293T cells), which emphasizes the importance of context in characterizing E3 
ligase activity paradigms. In 293T cells, FBXL21 was found to be the active E3 
ligase, whereas FBXL3 increased TCAP stability increased TCAP protein 
expression. TCAP protein stability was still negatively affected by FBXL21 co-
expression in C2C12 cells; however, FBXL3 was unexpectedly found to also be a 
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weaker, but still active E3 ligase in TCAP ubiquitin-mediated protein degradation 
(Figure 7). TCAP, when co-expressed with either FBXL3 or FBXL21, exhibited a 
decrease in protein stability and therefore a shorter half-life. This differential 
degradation pattern was noted as early as the 2-hour CHX treatment time point. 
TCAP was nearly diminished after 6 hours of CHX treatment, so half-life 
quantification is based on 4 hours of CHX treatment. Here, we observed that both 
FBXL3 and FBXL21 were active E3 ligases, although FBXL21 was the stronger, 
more efficient ligase. 
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Figure 6: Two homologous E3 ligases expression increases TCAP degradation in 
C2C12 myoblasts. C2C12 myoblasts were co-transfected with the constructs indicated 
above. 24 hours later, these cells were treated with 40ug/mL cycloheximide and 
harvested at either 0, 2, 4, or 6 hours post-treatment. Western Blotting was performed to 
detect TCAP protein levels under three conditions in addition to GAPDH for loading 
control. Left: representative Western Blots of TCAP protein expression, bottom: 
quantification of representative Western Blots. Half-life of TCAP protein was determined 
by non-linear, one-phase exponential decay analysis. TCAP half-life alone: 2.277 hr, 
TCAP + FBXL3: 1.914 hr, TCAP + FBXL21: 1.392. One-way ANOVA shows no significant 
difference in half-lives, but there is a noticeable difference at time points 2 and 4 hr.  
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3.4 Lentiviral constructs expressing FBXL3 and FBXL21 are functional in vitro 
To achieve sufficient overexpression in C2C12 cells, we chose a lentiviral 
system. These lentiviral constructs will be used for future experiments investigating 
the cellular function and biochemical mechanism of FBXL3/21 in in vitro models of 
skeletal muscle. I have created two lentiviral constructs expressing FBXL3 and 
FBXL21 by first removing the FBXL3/21 inserts from their original vector, pCMV10-
3XFlag (Sigma) and subcloning them into a pFUW lentiviral vector that allows for 
lentiviral transduction when introduced into HEK293T cells with two packaging 
vectors, pCMV-deltaR8.91 and pVSV-G. This final aim of creating the lentiviral 
constructs expressing FBXL3/21 was necessary for further in vitro studies.  
After subcloning was complete, small aliquots of each plasmid were 
submitted to GeneWiz for sequencing. Once sequencing was confirmed, plasmids 
were transduced in HEK293T cells and cells were harvested 24 hours post-
transduction. As shown in Figure 8, both FBXL3/21 were successfully subcloned and 
expressed in vitro. Adequate protein levels were detectable via both Western blotting 
analysis and confocal microscopy. 
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Figure 5: FBXL-expressing lentiviral constructs are functional in vitro. (A) top: representative 
Western Blot of FBXL3, bottom: representative GFP image expressing Fbxl3 cDNA. (B) top: 
representative Western Blot of FBXL21, bottom: representative GFP image expressing Fbxl21 
cDNA. Lentiviral constructs expressing FBXL3/21 were transduced in HEK293T cells 17 hours later. 
24 hours post-transduction, GFP images were taken and cells were harvested for Western Blotting 
analysis. 
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CHAPTER 4: DISCUSSION & FUTURE DIRECTIONS 
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4. Discussion 
There are an estimated 600 E3 ubiquitin ligases in the human genome and 
the majority of them are understudied (Grabbe et al 2011; Harper et al 2012). 
Subsets of E3s share high sequence homology, thus allowing them to share one or 
more protein targets for proteasomal degradation. Yoo et al (2013) found that CRY 
proteins are substrates of both FBXL3 and FBXL21, two homologous F-box-
containing E3 ligases. Localization studies showed that FBXL3 predominantly 
resides in the nucleus, whereas FBXL21 resides in both the nucleus and the 
cytoplasm. When present with its substrate, FBXL3 acts as an active E3 ligase, 
targeting CRY for degradation; however; FBXL21 antagonizes this activity when 
present in the nucleus and actually protects CRY from degradation. On the other 
hand, FBXL21 is capable of targeting CRY for proteasomal degradation in the 
cytoplasm, although less efficiently than FBXL3. This discovery lead to the 
elucidation of a previously unknown paradigm for homologous mammalian E3 
ligases. To further understand the cellular function(s) of this pair, we conducted a 
Yeast 2-Hybrid screen in skeletal muscle to find additional shared substrates and we 
identified TCAP as a novel shared target substrate of FBXL3 and FBXL21. We then 
aimed to elucidate the role of FBXL3 and FBXL21 in regulating muscle physiology 
via TCAP ubiquitin-mediated protein degradation. Here, we show that the circadian-
regulated FBXL21 is the more efficient E3 ligase in TCAP protein degradation, with 
implications for myogenesis in skeletal muscle.  
TCAP protein showed an oscillatory expression pattern, suggesting that it is 
circadian regulated in both murine skeletal and cardiac muscle. TCAP has been 
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previously reported as a transcriptional target of circadian machinery, with both 
protein and gene expression peaking near the early dark phase in murine cardiac 
muscle (Podobed et al 2014), so our data is consistent with the literature. In both 
instances, peak expression was observed in the dark phase of the circadian cycle 
(CT 16), which is also the active phase for mice. Circadian rhythms influence genes 
that are responsible for transcription, metabolism, and myogenic capacity in skeletal 
muscle, allowing all of these processes to anticipate environmental changes, which 
is highly beneficial from an evolutionary perspective (Andrews et al 2010; Chatterjee 
et al 2011; Zhang et al 2012). In the heart, TCAP is vital to both mechanical and 
signaling processes (Zou et al 2006) and can lead to contractile and mechanical 
sensing defects when genetically ablated (Ibrahim et al 2013). Additionally, 
contractile performance in the heart has been reported to vary over time (Young et al 
2001), providing even more evidence that the circadian system heavily influences 
the muscular system. Taken together, it can be deduced that the circadian system 
functions to maintain normal cardiac functioning. Based on our differentiation 
experiments, we assume the same is true for circadian regulation of TCAP protein in 
skeletal muscle. In gastrocnemius muscle, TCAP protein expression peaks at the 
time that FBXL21 protein expression is lowest, while FBXL3 protein expression 
remains relatively constant. This finding suggests that TCAP undergoes double 
circadian regulation—transcriptionally and post-translationally (protein degradation).  
The phenotype of the Psttm mouse might be interesting to investigate given 
the proposed relationship of TCAP and FBXL21 in muscle tissue. As previously 
stated, the Psttm mouse has a semidominant, hypomorphic mutation in the Fbxl21 
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gene. This mutation is expected to affect the LRR domain of FBXL21 protein, which 
is likely to affect substrate recognition and thus, protein-protein interactions (Yoo et 
al 2013). One striking feature of the Psttm mutant mouse is the size difference that is 
evident from birth. The weaning date is typically extended up to 7 days for these 
mice because they are smaller than normal pups. Again, skeletal muscle accounts 
for about 45% of the body (Goodpaster et al 2000; Hoppeler and Fluck 2002), so if 
there is a deficiency in skeletal muscle development (and possibly function) due to 
ineffective E3 ligase regulation of TCAP by FBXL21, this could potentially contribute 
to the low bodyweight observed in Psttm mice. Preliminary weight measurements of 
Psttm WT and homozygote littermates (data not shown) are consistent with this 
observation; further detailed investigation of the skeletal muscle phenotype in Psttm 
mice will be conducted in the future. 
Another important finding is that both FBXL3 and FBXL21 appear to act as 
active E3 ligases in C2C12 myoblasts, although FBXL21 is the more potent of the 
two (pictured in Figure 8). This was unexpected on two fronts: 1) FBXL3 was the 
only known active E3 ligase in CRY-targeted proteasomal degradation and 2) our 
preliminary experiments in 293T cells lead us to believe that only FBXL21 would be 
the active E3 ligase for TCAP proteasomal degradation. Given the current literature 
about TCAP’s role in cardiac and skeletal muscle, this paradigm is most likely to 
affect myogenesis & subsequent muscle functioning. Upon further scrutiny of these 
results, it is quite possible that FBXL3 and FBXL21 are both degrading TCAP protein 
in these cells because we analyzed the whole cell lysate. TCAP is known to be a 
cytoplasmic protein (Valle et al 1997); however, we have yet to directly check where 
40 
 
this protein localizes when overexpressed. Limb girdle muscular dystrophy type 2G 
(LGMD2G) patients have been found to lack TCAP protein in the sarcomeric regions 
in type 1 and 2 fibers obtained from muscle biopsies, but instead some anti-
telethonin fluorescence labeling was present in nuclei. It is, however, important to 
note that these patients all have autosomal recessive mutations in Telethonin 
(TCAP) (Vainzof et al 2002). If overexpressed TCAP does translocate to the nucleus 
at some point, FBXL3 might be a less efficient E3 ligase that only functions in the 
nucleus, causing us to observe both E3 ligases activities at once. Nevertheless, this 
finding is interesting and emphasizes the importance of substrate specificity for 
characterizing E3 ligases and their substrate-ligase paradigm. 
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Figure 8: The role of FBXL3 & FBXL21 in muscle physiology. Our data suggests 
that FBXL3 and FBXL21 both accelerate TCAP protein degradation. Moreover, TCAP 
is more rapidly degraded in the presence of FBXL21, a protein that is circadian 
regulated and primarily cytoplasmic. FBXL3 is also capable of promoting proteasomal 
degradation of TCAP, but to a lesser extent than FBXL21.  
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Broadly speaking, there are multiple lines of evidence suggesting that skeletal 
muscle is circadian regulated; however, there is still no definitive answer to the 
question, “Why is muscle circadian regulated?” Some studies have, however, 
provided some insight into this phenomenon. CLOCK, an important component of 
the circadian molecular oscillator, has been shown to play an important role in 
mitochondrial maintenance in skeletal muscle. Moreover, mice with a genetic 
disruption in the Clock gene exhibited a diminished ability to recover from chronic 
exercise. Interestingly, this inability to adapt to chronic exercise was reduced after 
endurance training (Pastore and Hood 1985). Since then, exercise has been shown 
to be a non-photic entrainment cue of the circadian system as evidenced in 
Schroeder et al (2012). Scheduled exercise had various effects on wildtype and VIP-
deficient mice, but notably it enhanced the phase and amplitude of 
PER2::LUCIFERASE expression rhythms in both the core and peripheral clocks of 
the Per2::Luc mice. Considering these findings and the many functions of skeletal 
muscle throughout the body, it is possible that circadian regulation of skeletal muscle 
has implications for metabolic functioning, circadian rhythm synchrony, locomotor 
activity, and mitochondrial functioning. The specific role of TCAP in relation to 
circadian regulation still remains elusive, but it most likely has the largest influence in 
mechanical stability or mechano-sensing.  
4.1 Future Directions 
Based on these findings, there are several directions to explore. Although we 
revealed the role that FBXL3 and FBXL21 play in TCAP protein degradation, the 
spatiotemporal mechanism has yet to be fully elucidated. Where do the SCFTCAP, 
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SCFFBXL3, and SCFFBXL21 complexes localize and at what times do these complexes 
form? Because both FBXL3 and FBXL21 were found to facilitate degradation of 
TCAP to similar degrees, we assume that both E3 ligases form SCF complexes; 
however, this has not been confirmed. We expect that FBXL3 is predominantly 
present in the nucleus and forms an SCF complex with Skp1 and Cul1, but is a 
weaker E3 ligase because TCAP is a cytoplasmic protein (Valle et al 1997). We also 
expect FBXL21 to form an SCF complex in the cytoplasm because it has been found 
to do so in the past (Yoo et al 2013). In light of the in vitro results, a closer 
examination of the Past-time mouse model is also warranted to better understand 
the physiological impact of TCAP post-translational regulation via FBXL3 and 
FBXL21 E3 ligase activity. How does the skeletal muscle develop in young and adult 
Past-time (Fbxl21 mutant) and Overtime (Fbxl3 mutant) mice compared to WT 
mice? Other potential avenues of investigation include ubiquitin chain linkage type 
and other shared substrates based on the Yeast 2-Hybrid screen. 
Our next experimental aim is to determine whether FBXL3 and/or FBXL21 
affects muscle differentiation in vitro. We will infect C2C12 myoblast cells with a 
lentivirus expressing either FBXL3 or FBXL21 and visualize the subsequent effects 
on myotube differentiation. I have created two lentiviral constructs expressing FBXL3 
and FBXL21, so the next step is to transfect these plasmids with two packaging 
vectors (pCMV-deltaR8.91 and pVSV-G) into 293T cells, harvest the virus and 
concentrate it with the Lenti-X Concentrator (ClonTech). To objectively measure the 
effect of overexpressing these E3 ligases, we will harvest muscle cells and measure 
the expression levels of differentiation markers and endogenous TCAP over the 
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course of the differentiation process. We hypothesize that FBXL21 overexpression 
will promote rapid TCAP degradation & therefore hinder muscle differentiation. 
 TCAP is a newly identified shared target substrate of FBXL3 and FBXL21. It’s 
importance to the anatomy and physiology of skeletal muscle implies that E3 ligase 
regulation of TCAP degradation serves an important physiological purpose. 
Interestingly, TCAP protein expression is highest when FBXL21 protein expression 
is low, which we reason that TCAP accumulation can occur in the absence of its E3 
ligase, FBXL21. When co-transfected with TCAP, FBXL3 and FBXL21 both 
decrease TCAP protein half-life, suggesting that they affect TCAP protein stability 
via ubiquitin-mediated protein degradation. These results were initially surprising 
because FBXL3 was the primary, active E3 ligase in CRY ubiquitin-mediated protein 
degradation. More importantly, the reversal of roles highlights the importance of 
substrate specificity in characterizing homologous E3 ligase paradigms. These two 
paradigms may serve as a guide for future mechanistic studies of other understudied 
E3 ligases.  
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